In recent years, the pharmaceutical industry has undergone intense criticism from a myriad of opponents from President Clinton to the common citizen. In fact, Bill Clinton included comprehensive health care reform in his election platform, and the pharmaceutical industry with its high profits has emerged as a scape goat in this debate. Recent developments, including Congress' delay of any legislative health care reform and the election of a Republican majority in both houses of Congress, have decreased the short run potential of any comprehensive health care reform. However, because of the rising costs associated with health care, some sort of comprehensive legislation is likely to occur within the next decade.
Taylor '95, David, "The Case for High Returns: A Study of the U.S. Pharmaceutical Industry" (1995). Honors Projects. Paper 5.